deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT03067129

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Sponsor: AbbVie

Conditions Hepatitis C Virus (HCV)
Interventions Glecaprevir + Pibrentasvir Pediatric Formulation Glecaprevir/Pibrentasvir Adult Formulation
Updated 34 times since 2017 Last updated: Apr 12, 2023 Started: Mar 20, 2017 Primary completion: May 21, 2020 Completion: Sep 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hepatitis C Virus (HCV), this trial is completed. The trial is conducted by AbbVie and has accumulated 34 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Oct 2022 · 3 months · monthly snapshot~Oct 2022 – ~Jun 2023 · 8 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

34 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Oct 2022 — Jun 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 29 earlier versions

  1. Jul 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Phase: PHASE3 → PHASE2_PHASE3

  6. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  10. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  11. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  12. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  13. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  14. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  15. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  16. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  17. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  19. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  20. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  21. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  22. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  23. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  24. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  25. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  26. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  27. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  28. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  29. Mar 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Berlin, Germany , Birmingham, United Kingdom , Boston, United States , Bunkyo-ku, Japan , Calgary, Canada , Chapel Hill, United States , Cincinnati, United States , Edmonton, Canada and 26 more locations